|PRODUCT NAME||CATALOG #||UNIT||PRICE||QTY||FAVORITES|
|galectin-3 Antibody (B2C10)||sc-32790||200 µg/ml||$279.00||
|galectin-3 Antibody (B2C10) Alexa Fluor® 488||sc-32790 AF488||200 µg/ml||$314.00||
|galectin-3 Antibody (B2C10) Alexa Fluor® 647||sc-32790 AF647||200 µg/ml||$314.00||
|Galectin-3 Antibody (B2C10) FITC||sc-32790 FITC||200 µg/ml||$292.00||
|galectin-3 Antibody (B2C10) HRP||sc-32790 HRP||200 µg/ml||$279.00||
|Galectin-3 Antibody (B2C10) PE||sc-32790 PE||200 µg/ml||$303.00||
|galectin-3 Antibody (B2C10) L||sc-32790 L||200 µg/0.1 ml||$279.00||
See how others have used galectin-3 Antibody (B2C10). Click on the entry to view the PubMed entry .
PMID: # 26131603
Ralhan, R. et al. 2015. Immunohistochemical Subcellular Localization of Protein Biomarkers Distinguishes Benign from Malignant Thyroid Nodules: Potential for Fine-Needle Aspiration Biopsy Clinical Application. Thyroid. 25: 1224-34.
PMID: # 23184915
Sun, L. et al. 2013. Functional screen for secreted proteins by monoclonal antibody library and identification of Mac-2 Binding protein (Mac-2BP) as a potential therapeutic target and biomarker for lung cancer. Molecular & cellular proteomics : MCP. 12: 395-406.
PMID: # 22367363
Xie, L. et al. 2012. The expressions and clinical significances of tissue and serum galectin-3 in pancreatic carcinoma. Journal of cancer research and clinical oncology. 138: 1035-43.
PMID: # 20433713
Gassmann, P. et al. 2010. In vivo tumor cell adhesion in the pulmonary microvasculature is exclusively mediated by tumor cell--endothelial cell interaction. BMC Cancer. 10: -.
PMID: # 20480503
Burton, OT. et al. 2010. Importance of TLR2 in the direct response of T lymphocytes to Schistosoma mansoni antigens. Eur. J. Immunol.. 40: 2221-2229.
PMID: # 20698585
Zhou, JY. et al. 2010. Galectin-3 is a candidate biomarker for amyotrophic lateral sclerosis: discovery by a proteomics approach. J. Proteome Res.. 9: 5133-5141.
PMID: # 19107770
Fernandez-Ranvier, GG. et al. 2009. Defining a molecular phenotype for benign and malignant parathyroid tumors. Cancer. 115: 334-344.
PMID: # 19995719
Ostalska-Nowicka, D. et al. 2009. Expression of galectin-3 in nephrotic syndrome glomerulopaties in children. Folia Histochem. Cytobiol.. 47: 315-322.
PMID: # 19706805
Hu, H. et al. 2009. Tumor cell-microenvironment interaction models coupled with clinical validation reveal CCL2 and SNCG as two predictors of colorectal cancer hepatic metastasis. Clin. Cancer Res.. 15: 5485-5493.
PMID: # 17785480
Breuilh, L. et al. 2007. Galectin-3 modulates immune and inflammatory responses during helminthic infection: impact of galectin-3 deficiency on the functions of dendritic cells. Infect. Immun.. 75: 5148-5157.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2016 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.